Neonate respiratory distress syndrome Neonatal Diseases Neonate respiratory distress syndrome
Conditions
Interventions
11.4 mg Celestone Chronodose or saline placebo
Sponsors
The University of Adelaide (Australia)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Women with a singleton, twin or triplet pregnancy 2. Gestational age less than 32 weeks who have received initial treatment of corticosteroid seven or more days ago 3. Responsible clinician considers her to be at continued risk of preterm birth 4. Informed, written signed consent 5. No contraindication to further corticosteroid therapy
Exclusion criteria
Exclusion criteria: 1. Women with chorioamnionitis requiring urgent delivery 2. Women in whom the L/S ratio or equivalent test, if determined, is judged to be mature 3. Women who are in the second stage of labour 4. Women in whom corticosteroid therapy is considered essential 5. No contraindication to further corticosteroid therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Neonatal respiratory outcomes: 1. Birthweight 2. Length and head circumference at birth 3. Primary discharge from hospital | — |
Secondary
| Measure | Time frame |
|---|---|
| On the mother: 1. Clinical chorioamnionitis requiring intrapartum antibiotics, maternal postpartum pyrexia greater than 38.0°C 2. Other measures of morbidity On the infant: Other measures of foetal and neonatal morbidity. | — |
Countries
Australia
Outcome results
None listed